TM
LGND icon

Torren Management’s Ligand Pharmaceuticals LGND Stock Holding History

Torren Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.16K Hold
10
– – ﹤0.01% 450
2026
Q1 		$2K Sell
10
-113
-92% -$22.4K ﹤0.01% 553
2025
Q4 		$23.3K Buy
+123
New +$23.6K 0.01% 537

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Torren Management's LGND Position: Q2 2026 in Review

Torren Management held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 10 shares worth $3.16K. The position accounts for ﹤0.01% of the portfolio, ranked #450.

Torren Management first reported a position in LGND in Q4 2025 and has held it in 3 quarters since. The position peaked at $23.3K in Q4 2025. 192 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Torren Management held 10 shares of Ligand Pharmaceuticals worth $3.16K as of Q2 2026.
  • Torren Management left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
  • Ligand Pharmaceuticals made up ﹤0.01% of Torren Management's portfolio in Q2 2026, its #450 holding.
  • Torren Management first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Torren Management's Ligand Pharmaceuticals position peaked at $23.3K in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Torren Management's 13F filing for Q2 2026, filed 10 Jul 2026.